Molecular typing—new targets and therapy options for upper GI carcinomas with a focus on adenocarcinomas of the esophagus, gastroesophageal junction, and stomach
Conflict of interest
K. Schmitz received honoraria as advisor or speaker from: Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Diaceutics, Incyte, Janssen-Cilag, Eli Lilly, Merck, Merck Sharp and Dohme, Novartis Pharma, Pfizer, PharmaMar, Roche Pharma, Servier, Stemline, Takeda, Targos GmbH, and ZytoVision. K. S. received travel support from AstraZeneca, Merck, Novartis and PharmaMar.
Comments (0)